Critical appraisal of trastuzumab in treatment of advanced stomach cancer

Item

http://www.wikidata.org/entity/Q24604411

description

2011 nî lūn-bûn

@nan

2011 թուականին հրատարակուած գիտական յօդուած

@hyw

2011 թվականին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Critical appraisal of trastuzumab in treatment of advanced stomach cancer

@ast

Critical appraisal of trastuzumab in treatment of advanced stomach cancer

@en

Critical appraisal of trastuzumab in treatment of advanced stomach cancer

@nl

type

Item

label

Critical appraisal of trastuzumab in treatment of advanced stomach cancer

@ast

Critical appraisal of trastuzumab in treatment of advanced stomach cancer

@en

Critical appraisal of trastuzumab in treatment of advanced stomach cancer

@nl

prefLabel

Critical appraisal of trastuzumab in treatment of advanced stomach cancer

@ast

Critical appraisal of trastuzumab in treatment of advanced stomach cancer

@en

Critical appraisal of trastuzumab in treatment of advanced stomach cancer

@nl

P1476

Critical appraisal of trastuzumab in treatment of advanced stomach cancer

@en

P2093

Heather-Jane Au

http://www.w3.org/2001/XMLSchema#string

Judith Meza-Junco

http://www.w3.org/2001/XMLSchema#string

Michael B Sawyer

http://www.w3.org/2001/XMLSchema#string

P2860

Humanization of an anti-p185HER2 antibody for human cancer therapy

Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Cardiac dysfunction in the trastuzumab clinical trials experience

Trastuzumab--mechanism of action and use in clinical practice

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer.

A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer.

P304

57-64

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CMR.S12698

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21556317

http://www.w3.org/2001/XMLSchema#string

P932

3085240

http://www.w3.org/2001/XMLSchema#string